Schodack Landing, NY, United States of America

Richard Christopher Oglesby


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • Poway, CA (US) (2002)
  • Schodack Landing, NY (US) (2006)

Company Filing History:


Years Active: 2002-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Richard Christopher Oglesby: Innovator in Substituted Pyrazolopyrimidines

Introduction

Richard Christopher Oglesby is an esteemed inventor based in Schodack Landing, NY. With a strong focus on pharmaceutical innovations, he has made significant contributions to the field through his inventive prowess. Oglesby holds two patents that reflect his commitment to advancing medicinal chemistry.

Latest Patents

Oglesby's latest patents include advancements in the synthesis of substituted pyrazolopyrimidines. Specifically, he has developed methods for creating N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide. These compounds have broad utility, particularly in the treatment of insomnia. His work emphasizes improved techniques that eliminate the need for isolating the pyrazole intermediate. This innovation presents significant advantages in terms of efficiency, especially in large-scale manufacturing processes.

Career Highlights

Oglesby is currently employed at Neurocrine Biosciences, Inc., where he continues to drive innovation in the pharmaceutical sector. His career reflects a deep dedication to enhancing therapeutic solutions through chemical research and development.

Collaborations

Throughout his career, Richard has collaborated with talented individuals such as Raymond Stanley Gross and Keith M Wilcoxen. These partnerships have fostered a collaborative environment that nurtures creativity and facilitates the successful development of new compounds.

Conclusion

Richard Christopher Oglesby stands out as a prominent inventor in the realm of substituted pyrazolopyrimidines. His innovative contributions have the potential to transform therapeutic approaches, particularly in addressing sleep-related disorders. Oglesby's ongoing research and dedication to pharmaceutical advancements continue to shape the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…